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Abstract
 
Nuclear factor (NF)-
 
 
 
B proteins play crucial roles in immune responses and cellular survival.
Activation of NF-
 
 
 
B is mediated by the I
 
 
 
B kinase (IKK) complex, which is composed of two
kinases, IKK1 and IKK2, and a regulatory subunit termed NF-
 
 
 
B essential modulator
 
(
 
NEMO). IKK2- and NEMO-deficient mice die at early embryonic stages. We therefore used
conditional gene targeting to evaluate the role of these proteins in B cells in adult mice. B lin-
eage–specific disruption of either IKK signaling by deletion of NEMO, or of IKK2-specific
signals by ablation of IKK2 activity leads to the disappearance of mature B lymphocytes. We
conclude that maintenance of mature B cells depends on IKK-mediated activation of NF-
 
 
 
B.
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Introduction
 
The NF-
 
 
 
B/Rel transcription factor family regulates the
 
expression of genes playing critical roles in cell activation, pro-
liferation, and survival. In mammals it consists of five different
 
Rel proteins: p65/RelA, c-Rel, RelB, p50/NF-
 
 
 
B1, and
p52/NF-
 
 
 
B2; the latter two are generated through pro-
teolytic processing of their respective precursor molecules
p105 (p50) and p100 (p52). These subunits form various
hetero- or homodimeric complexes, which in most resting
cells are kept inactive sequestered to the ankyrin repeats of
 
inhibitory molecules termed inhibitor of NF-
 
 
 
Bs (I
 
 
 
Bs)
 
*
 
(1). The precursors of NF-
 
 
 
B1 and NF-
 
 
 
B2 also contain
ankyrin repeats and therefore can act as inhibitors of Rel
proteins (2). Activation of the NF-
 
 
 
B signaling pathway
ultimately leads to the phosphorylation and subsequent
polyubiquitination and proteasome-mediated degradation
of the I
 
 
 
Bs, releasing NF-
 
 
 
B that then accumulates in the
nucleus where it activates transcription from its target
genes, including genes encoding proinflammatory cyto-
kines and chemokines, cell-adhesion molecules and anti-
apoptotic proteins (3). The inducible phosphorylation of
I
 
 
 
B in response to most known stimuli is mediated by the
 
I
 
 
 
B kinase (IKK)-signalsome, a kinase complex consist-
ing of two kinases, IKK1 and IKK2, and a regulatory sub-
unit termed NF-
 
 
 
B essential modulator (NEMO) or
IKK
 
 
 
 (4, 5).
Activated Rel proteins are involved in important and di-
verse functions of B cells, such as proliferation, isotype
switching, and cytokine production (6–8). NF-
 
 
 
B is con-
stitutively active in mature B cells indicating that this sig-
naling pathway could be important for B cell maintenance.
Indeed early studies using gene targeting technology
 
showed that mice deficient for more than one of the NF-
 
 
 
B
subunits have defects in B cell development. Adoptive
transfer experiments using fetal liver cells of p50/p65 dou-
ble knockout mice resulted in absence of B lymphopoiesis.
However, when p50
 
 
 
/
 
 
 
p65
 
 
 
/
 
 
 
 fetal liver cells were mixed
with WT bone marrow (BM) cells they gave rise to mature
B cells in the spleen, demonstrating that this phenotype is
non cell autonomous (9). More detailed studies using simi-
lar adoptive transfer experiments of mixed fetal liver cells
showed that p50
 
 
 
/
 
 
 
 or p50
 
 
 
/
 
 
 
p65
 
 
 
/
 
 
 
 B cells cannot de-
velop into marginal zone (MZ) B cells (10). In p50/p52
double knockout mice B cell development is blocked at
the immature transitional stage, shortly after B cells exit
from the BM (11). Similarly RelA
 
 
 
/
 
 
 
c-Rel
 
 
 
/
 
 
 
 fetal liver
 
cells fail to give rise to IgM
 
low
 
IgD
 
 
 
 mature B cells.
RelA
 
 
 
/
 
 
 
c-Rel
 
 
 
/
 
 
 
 immature (IM) B cells undergo acceler-
ated cell death in culture and express abnormally low levels
of Bcl-2 (12). Furthermore, B cell–specific inhibition of
NF-
 
 
 
B activity by transgenic expression of a trans-domi-
 
M. Pasparakis and M. Schmidt-Supprian contributed equally to this work.
 
Address correspondence to Klaus Rajewsky, Center for Blood Research
Harvard Medical School, 200 Longwood Ave., Boston, MA 02115. Phone:
617-278-3132; Fax: 617-278-3129; E-mail: rajewsky@cbr.med.harvard.edu
 
*
 
Abbreviations used in this paper:
 
 BCR, B cell receptor; BM, bone
marrow; BrdU, 5
 
 
 
-bromo-2
 
 
 
-deoxyuridine; FO, follicular; I
 
 
 
B, inhibitor
of NF-
 
 
 
B; IKK, I
 
 
 
B kinase; IM, immature; MZ, marginal zone; NEMO,
NF-
 
 
 
B essential modulator. 
744
 
I
 
 
 
B Kinase Signaling is Essential for Maintenance of Mature B Cells
 
nant form of I
 
 
 
B-
 
 
 
 leads to a reduction of mature splenic
B cells and recirculating B220
 
high
 
IgM
 
 
 
 BM cells (13). Mice
deficient for p50 have normal numbers of follicular (FO) B
cells (10). It has been shown, however, that the in vivo
turnover of p50
 
 
 
/
 
 
 
 B cells is increased compared with WT
B cells (14, 15). Whether this is due to a defect intrinsic to
the B cell lineage or to a defect in other cell types is not
clear. Ex vivo isolated p50-deficient B cells die faster than
WT B cells, indicating that p50 could play a role in mature
B cell survival. However, a direct analysis of whether ma-
ture B cells, once generated, depend on NF-
 
 
 
B–mediated
survival signals in a cell-autonomous fashion in vivo, has
not been performed so far.
Most signals that activate NF-
 
 
 
B converge at the IKK
complex. It has been shown that B cells lacking IKK1 ac-
tivity are short-lived and have a reduced capacity to prolif-
erate. Very few IKK1-deficient B cells develop into
IgD
 
 
 
IgM
 
low
 
 mature B cells in the spleen (16, 17). IKK1 is
dispensable for cytokine-induced activation of NF-
 
 
 
B by
degradation of I
 
 
 
B, but is critical for the generation of p52
from its precursor p100 (17). It is, however, controversial
whether there is an overall reduction of NF-
 
 
 
B binding
activity in IKK1-deficient B cells (16) or whether the mat-
uration defect is solely due to lack of processing of p100 to
p52(17). IKK2 and NEMO-deficient mice die at early em-
bryonic stages showing massive liver degeneration (18–23).
Studies in embryonic fibroblasts revealed that lack of IKK2
leads to strongly reduced activation of NF-
 
 
 
B in response
to proinflammatory cytokines, whereas absence of NEMO
completely abolishes this activation (18–23). The 
 
Nemo
 
gene is located on the X-chromosome and heterozygous
NEMO knockout mice develop a progressive skin disease
that closely resembles the human X-linked genodermatosis
incontinentia pigmenti (IP; references 20, 21, and 24). This
disease is characterized by the complete skewing of X-inac-
tivation in peripheral blood leukocytes (25), possibly due to
selection against NEMO-deficient leukocytes. Chimeras
generated from NEMO-knockout ES cells have no ES
cell–derived B and T cells in the blood, indicating that
NEMO could be essential for the development or survival
of these cells (21). 
 
Ikk2
 
 
 
/
 
 
 
 radiation chimeras lack periph-
eral blood B cells (26), similarly to the p50/p65 double
knockout radiation chimeras (9), but it is not clear yet
whether the inability of IKK2-deficient fetal liver cells to
give rise to B cells is a B cell–autonomous phenomenon or
not. In transgenic mice expressing a dominant-negative
version of IKK2 specifically in B cells, B cells develop nor-
mally but show defects in proliferation and antibody re-
sponses (27). Thus, whereas IKK1 is important for the gen-
eration of mature B cells, the role of IKK2 is controversial
and little is known about the importance of NEMO in B
cell development. Whether activation of NF-
 
 
 
B through
IKK is also essential for maintenance of mature B cells re-
mains unresolved.
The assessment of the role of IKK2 and NEMO in tis-
sues of adult mice is compromised by the early lethality of
homozygous knockout mice. We opted to circumvent this
problem by using the approach of conditional gene target-
 
ing, which allows the deletion of genes in specific cell types
of the adult mouse (28). Using B cell–restricted expression
of Cre recombinase we specifically ablated NEMO or
IKK2 in B lymphocytes in order to investigate the role of
these molecules in B cell development and function. We
show here that interference with either NEMO or IKK2
activity is incompatible with B cell survival in the spleen.
 
Materials and Methods
 
Mice.
 
Mice carrying 
 
Ikk2
 
D
 
 and 
 
Ikk2
 
 
 
K
 
D
 
 alleles were gener-
ated by crossing 
 
Ikk2
 
FL
 
 and 
 
Ikk2
 
 
 
K
 
FL
 
 mice to a Cre-deleter strain
(29). All mice were housed in the conventional animal facility of
the Institute for Genetics.
 
Flow Cytometry.
 
Cells obtained from the various lymphoid
organs were surface-stained with combinations of fluorochromes
(FITC, PE, Cy-Chrome, PerCP, and/or allophycocyanin) or bi-
otin-conjugated mAbs for 20 min on ice. Stainings with biotinyl-
ated mAbs were followed by a secondary staining with either
Streptavidin-Cy-Chrome (BD Biosciences) or Streptavidin-
PERCP (Becton Dickinson). Stained cells were acquired on a
FACScan™ or FACSCalibur™ and data were analyzed using
CELLQuest™ software (Becton Dickinson). Dead cells were la-
beled with propidium iodide or Topro-3 (Molecular Probes) and
excluded from the analysis.
Monoclonal antibodies R33–24.12 (anti-IgM), 1.3–5
 
 
 
(anti-
IgD), RA3–6B2 (anti-B220), and 30F1 (anti-HSA) were pre-
pared and conjugated in our laboratory. Monoclonal antibodies
to CD5, TCR
 
 
 
, CD19, CD21/CD35, CD23, CD43, CD69,
Fas, and CD86 were purchased from BD Biosciences.
For cell sorting B cells were purified by MACS (Miltenyi Bio-
tec) and then stained with antibodies against various cell surface
markers. B cells of individual B cell subsets were then sorted us-
ing a dual laser FACStar™ (Becton Dickinson). MACS-isolated
B cells were typically 
 
 
 
90% pure and sorted B cell subpopula-
tions were 
 
 
 
95% pure.
 
5
 
 
 
-Bromo-2
 
 
 
-Deoxyuridine Labeling.
 
Mice were fed with 5
 
 
 
-
bromo-2
 
 
 
-deoxyuridine (BrdU; Sigma-Aldrich) in the drinking
water (1 mg/ml) for 1 or 1 wk. Splenocytes were stained with
FITC-conjugated anti-B220 mAbs (clone RA33.A1.CL6) and
fixed with 70% methanol followed by 2% formalin in PBS. Cells
were then treated with 1 M HCl/0,5% Tween 20 for 15 min at
37
 
 
 
C followed by 0,1% Na
 
2
 
B
 
4
 
O
 
7
 
. Cells were finally stained with
a biotin-conjugated anti-BrdU mAb (Alexis Biochemicals) and
streptavidin-Cychrome and analyzed with a FACSCalibur™
(Becton Dickinson).
 
Anti–IL-7 Receptor Antibody Injections.
 
Mice were injected in-
travenously with 1 mg of anti–IL-7 receptor (anti-IL-7R) mAb
(clone A7R34) every other day for 4 wk before sacrifice. Cell
suspensions from the various lymphoid organs were analyzed by
FACS
 
®
 
. DNA isolated from MACS-purified splenic B cells was
analyzed with Southern blotting.
 
Results
 
Description of the Conditional Mouse Strains Used in This
Study.
 
Mice with conditional 
 
nemo
 
 alleles (
 
nemo
 
FL
 
) were
generated as described (21). For the 
 
Ikk2
 
 gene we gener-
ated two different mouse strains, designated 
 
Ikk2
 
FL/FL
 
 and
 
Ikk2
 
 
 
K
 
FL/FL
 
. The 
 
ikk2
 
FL
 
 allele was generated by placing
exons 6 and 7 of the Ikk2 gene between loxP sites. Cre-745 Pasparakis et al.
mediated deletion of these two exons leads to an ikk2 null
allele that does not produce any IKK2 protein (30).
In the absence of IKK2 IKK complexes consist of
NEMO associated with IKK1 homodimers and exhibit in-
ducible kinase activity (5, 31). To eliminate IKK2 kinase
activity without disrupting IKK stoichiometry we therefore
decided to generate another conditional ikk2 allele, which
allows replacement of IKK2 by a kinase-dead molecule
(IKK2 K) upon Cre-expression. This allele (ikk2 KFL)
was generated by placing only exon 7 of the Ikk2 gene be-
tween lox P sites. After deletion of exon 7, exons 6 and 8
splice in frame and the resulting mRNA produces a trun-
cated IKK2 protein lacking amino acids 160–189, which
include the two serines of the activation loop (Ser177, 181)
that are essential for the activation of the kinase (32; Fig. 1).
This IKK2 K protein lacks kinase activity and is incorpo-
rated into the IKK complex, but it is expressed at lower
levels compared with WT IKK2, presumably due to de-
creased protein stability (unpublished data). Inflammatory
cytokine–induced activation of NF- B, as measured by the
sensitivity of the cells to TNF-induced death and by assay-
ing production of IL-6 in response to IL-1 or LPS, is re-
duced in Ikk2 KD/D MEFs compared with IKK2 knockout
MEFs, but it is not completely abolished as in NEMO-
deficient MEFs (unpublished data). The generation and
characterization of the IKK2 K mutation will be described
in detail elsewhere.
To delete the loxP flanked nemo and ikk2 alleles in B
lymphocytes we used a transgenic mouse strain expressing
Cre recombinase under the control of the endogenous
CD19 locus (33). This CD19-Cre mouse has been shown
to delete loxP flanked alleles specifically in the B cell lin-
eage. The deletion efficiency was shown to be 75–80% in
BM and  95% in splenic B cells (33–35). The fact that de-
letion efficiency is higher in splenic than in BM B cells in-
dicates that Cre-mediated deletion is an ongoing process
during B cell development and maturation, leading to the
essentially complete deletion of loxP flanked alleles in ma-
ture B cells.
Flow Cytometric Analysis of the B Cell Compartment in
CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D, and -NemoFL/Y Mice.
Initial FACS® analysis of B cell populations in Ikk2FL/FL,
Ikk2FL/D,  Ikk2 KFL/FL,  Ikk2 KFL/D, and NemoFL/Y mice
did not show any differences compared with controls. To
facilitate Cre-mediated deletion, we used mice in which
only one loxP flanked allele remains to be deleted (CD19-
Cre/Ikk2FL/D, -Ikk2 KFL/D, and -NemoFL/Y) for our experi-
ments. FACS® analysis of B cell populations in these
mouse strains revealed very similar pictures. In the BM
early B cell development was essentially normal and the
only difference found compared with control mice was a
2–4-fold reduction of mature recirculating B cells (Fig. 2,
A and B). In the spleen, B cells were strongly reduced
leading to an inverted B/T cell ratio (Fig. 3, A and B). The
reduction seems to occur mainly in the IgMlowIgD  ma-
ture B cell population. Splenic B cells were then sub-
divided into immature (IM: CD21lowHSAhigh), follicu-
Figure 1. The conditional
ikk2 K allele. Schematic repre-
sentation of the WT ikk2 allele,
which produces WT IKK2 pro-
tein and the ikk2 K allele,
which after deletion of loxP-
flanked exon 7 generates a ki-
nase-dead version of IKK2
(IKK2 K). Open and filled
boxes represent exons, triangles
represent loxP sites, and the two
serines of the IKK2 activation
loop are indicated using the
amino acid single letter code.
Figure 2. FACS® analysis of BM B cell populations. (A) CD19-Cre/
Ikk2FL/D, Ikk2 KFL/D, and controls and (B) CD19-Cre/NemoFL/Y and
control mice. Genotypes are as indicated. Cell surface markers are shown
as coordinates and gated cell populations are indicated in brackets. The
numbers next to boxed lymphocyte populations refer to the percentages
of live cells in the lymphocyte gate.746 I B Kinase Signaling is Essential for Maintenance of Mature B Cells
lar (FO: CD21intHSAlow) and marginal zone (MZ:
CD21highHSAint) B cells according to CD21 and HSA ex-
pression (36). This analysis revealed that compared with
controls the FO B cells are the most diminished B cell
population in the spleens of CD19-Cre/Ikk2FL/D,
-Ikk2 KFL/D, and -NemoFL/Y mice (Fig. 3, A and B). Lymph
node B cells and both B1 and B2 cells in the peritoneal
cavity of these mice were also strongly reduced compared
with control mice (unpublished data).
Reduction of Absolute B Cell Numbers in Mice with B Cell–
specific Ablation of NEMO or IKK2. FACS® analysis re-
vealed a strong reduction of mature B cells in mice with B
cell–specific ablation of NEMO or IKK2. Calculation of
the absolute cell numbers of individual B cell populations
in the spleens of CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D, and
-NemoFL/Y mice revealed a 3–4-fold decrease in the total
number of splenic B cells in all mutant mouse strains com-
pared with controls (Fig. 4 A). FO and MZ B cells were
most severely affected (Fig. 4, C and D). Analysis of IM B
cells revealed a different picture in the three different
mouse strains. This population was not significantly af-
fected in CD19-Cre/Ikk2FL/D mice, while a clear reduction
was observed in CD19-Cre/NemoFL/Y mice and CD19-
Cre/Ikk2 KFL/D mice showed an intermediate picture
(Fig. 4 B).
Preferential Loss of Splenic B Cells of the Deleted Genotype
in CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D, and -NemoFL/Y Mice.
The strong decrease of peripheral B cell numbers in mice
with B cell specific ablation of NEMO or IKK2 activity
suggests that inhibition of IKK signaling interferes with the
development or persistence of B lymphocytes. However,
all different subpopulations of B cells are present in CD19-
Cre/Ikk2FL/D, -Ikk2 KFL/D, and -NemoFL/Y mice, although
in reduced numbers. One possible explanation for this
could be that the remaining cells persist because they have
escaped deletion of the loxP flanked alleles.
To investigate this hypothesis we performed Southern
blot analysis of DNA isolated from FACS®-purified BM
and splenic B cells populations from these three strains of
mice. This analysis revealed that between 64–76% of BM
IgM  B cells had deleted the loxP-flanked alleles (Fig. 5,
A–C). This result is in agreement with the previously re-
ported deletion efficiency of the CD19-Cre transgene in
the BM (33) and with deletion seen in CD19-Cre/Ikk2FL/WT
mice, in which deletion of the loxP-flanked allele has
no effect due to IKK2-expression from the remaining
WT allele (Fig. 5 D). Between 64–69% of the IgM  BM
B cells isolated from CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D,
and -NemoFL/Y mice carried the deleted genotype, com-
pared with an 87% deletion of the loxP-flanked allele in
CD19-Cre/Ikk2FL/WT mice. This indicates that IKK-
deleted IgM  BM B cells are counterselected, in accordance
with the reduced number of recirculating B cells in the
BM of these mice. Whereas deletion was very efficient in
splenic IM CD19-Cre/Ikk2FL/D and -Ikk2 KFL/D B cells
( 90%), only 44–66% of FO B cells were found to have
deleted the loxP flanked alleles (Fig. 5, A and B). In
CD19-Cre/Ikk2FL/WT mice deletion was 87 and 95% for
IM and FO B cells, respectively (Fig. 5 D). The finding
that within the FO B cell compartment there are less cells
with the deleted genotype than in the immature com-
partment suggests that B cells lacking IKK2 activity are
counterselected as they move on to become more mature
FO B cells (Fig. 5, A and B). In CD19-Cre/NemoFL/Y
mice deletion in IM splenic B cells was less efficient than
in the IKK2 loxP flanked alleles ( 70% compared with
 90%) and was not further reduced in FO B cells (Fig. 5
C). This indicates that the cells that delete the nemoFL al-
lele are already counter-selected at the immature B cell
stage. A more dramatic effect is seen in MZ B cells. In all
three mouse strains very few cells with deleted alleles
( 12%) were found within the marginal zone B cell pop-
Figure 3. FACS® analysis of splenic B cell populations. (A) CD19-Cre/
Ikk2FL/D,  Ikk2 KFL/D, and controls and (B) CD19-Cre/NemoFL/Y and
control mice. Genotypes are as indicated. Cell surface markers are shown
as coordinates and gated cell populations are indicated in brackets. The
numbers next to boxed lymphocyte populations refer to the percentages
of live cells in the lymphocyte gate.747 Pasparakis et al.
ulation, whereas in CD19-Cre/Ikk2FL/WT mice deletion
was virtually complete, suggesting that IKK activity is es-
sential for the development or maintenance of these cells
(Fig. 5, A–D).
Based on the above data we envisage the following sce-
nario: ongoing deletion continuously leads to the genera-
tion of B cells that have deleted the respective gene, but
still retain enough protein to stay alive. With time and
through turnover of endogenous mRNAs and proteins
these cells lose their ability to signal via the IKK complex
and die. Continuous influx of newly generated B cells from
the BM and continuous Cre-mediated deletion of the loxP
flanked alleles leads to the deletion pattern observed in B
cells of CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D, and -NemoFL/Y
mice. This scenario predicts a higher turnover rate of mu-
tant compared with control B cells.
Figure 4. Reduction of B cell numbers in
CD19Cre/IKK-conditional mice. Absolute
numbers of B cell subpopulations in the spleens
of CD19-Cre/Ikk2FL/D, CD19-Cre/Ikk2 KFL/D,
and CD19-Cre/NemoFL/Y compared with con-
trol mice are shown. (A) Total B cell numbers,
(B) IM B cells, (C) follicular B cells, and (D)
marginal zone B cells. Bar charts showing the
absolute cell numbers for the indicated B cell
population in the spleen for each of the follow-
ing mouse strains: CT (controls), IKK2 KO
(CD19-Cre/Ikk2FL/D), IKK2 DK (CD19-Cre/
Ikk2 KFL/D), and NEMO KO (CD19-Cre/
NemoFL/Y). For each group three to eight mice
were analyzed. Error bars indicate standard de-
viation. The absolute cell numbers for each
population were calculated by multiplying the
percentage of each B cell subset of all live sple-
nocytes obtained from the FACS® analysis with
the total number of live cells recovered from
the perspective spleen.
Figure 5. Counterselection against IkkD/D,
Ikk2 KD/D, and NemoD/Y B cells in the spleen.
Southern blot analyses of sorted splenic B cell pop-
ulations of mice of the indicated genotypes are
shown. (A) CD19-Cre/Ikk2FL/D mice, (B) CD19-
Cre/Ikk2 KFL/D mice, (C) CD19-Cre/NemoFL/Y
mice, (D) CD19-Cre/Ikk2 KFL/WT mice. T, tail;
IgM  (CD19 B220 IgM : pro- and pre-B cells);
IgM  (CD19 B220 IgM  B cells); IM (CD19 
CD21lowHSAhigh: immature B cells); FO
(CD19 CD21intHSA : follicular B cells); MZ
(CD19 CD21highHSAint: marginal zone B cells).
The percentage of deleted alleles and cells of the
deleted genotype is given below the blots. Each
blot is a representative example of at least four mice
analyzed. Del (%), percent of deleted alleles.748 I B Kinase Signaling is Essential for Maintenance of Mature B Cells
CD19-Cre/Ikk2 KFL/D and CD19-Cre/NemoFL/Y B Cells
Have Higher In Vivo Turnover Rates than WT Control B
Cells. To test this hypothesis we determined the percent-
age of BrdU-labeled B cells in the spleens of CD19-Cre/
Ikk2 KFL/D and control mice that had been fed with BrdU
for 1 wk (Fig. 6). In CD19-Cre/Ikk2 KFL/D 50 to 60% of
B lineage splenocytes had incorporated BrdU into their
DNA within this period of time, whereas in control mice
only 30% of these cells were BrdU-positive (Table I). This
result shows that B cell turnover in the spleen of CD19-
Cre/Ikk2 KFL/D mice is significantly faster than in WT an-
imals. Similarly, in CD19-Cre/NemoFL/Y mice twice as
many splenic B lymphocytes incorporated BrdU as B cells
of control mice, demonstrating that B cells in CD19-Cre/
NemoFL/Y mice also have an increased turnover rate (un-
published data). These results suggest that IKK mutant
splenic B cells have a shorter half-life then control B cells.
Blockade of De Novo B Cell Generation in CD19-Cre/
Ikk2 KFL/D Mice Leads to Disappearance of IKK2-deficient B
Cells from the Spleen. During B cell development periph-
eral B cells are continuously generated from the BM. We
decided to evaluate whether CD19-Cre/Ikk2 KFL/D B lin-
eage lymphocytes that underwent Cre-mediated deletion
can persist in the spleen by blocking influx of IM B cells
from the BM. This was achieved by injection of antagonis-
tic monoclonal antibodies against the IL-7R. This treat-
ment blocks B cell development at the pro-B cell stage and
thus abolishes the influx of IM B cells from the BM into
the periphery (37).
After four weeks of anti–IL-7R antibody administration
FACS® analysis demonstrated that B cell development in
the BM and the influx of newly generated B cells into the
spleen is indeed inhibited in antibody-treated mice (Fig. 7
A). Southern blot analysis of DNA isolated from purified
splenic B cells of these mice revealed the absence of cells
with Ikk2 KD/D genotype (Fig. 7 C), whereas in untreated
CD19-Cre/Ikk2 KFL/D mice 50 to 80% of the CD19-posi-
tive splenic B cells are of the deleted genotype (Fig. 7 B).
This finding validates the view that the B cells with two
deleted  ikk2 K alleles that are found in the spleens of
CD19-Cre/Ikk2 KFL/D mice are cells that have only re-
cently undergone Cre-mediated recombination and still re-
tain IKK2 protein. As soon as the influx from the BM is
blocked, no new B cells having freshly acquired the deleted
genotype enter the spleen from the BM. Within a period of
4 wk all B cells lacking IKK2 activity disappear from the
spleen and only cells that have escaped Cre-mediated dele-
tion of the loxP flanked alleles persist. These results dem-
onstrate that IKK-mediated NF- B activity is essential for
the survival of mature B cells.
Discussion
We investigated the role of IKK-induced NF- B activ-
ity in B cells by conditional inactivation of IKK2 and
NEMO. B cell specificity was achieved by crossing mice
carrying conditional NEMO and IKK2 alleles (Ikk2FL/D,
Ikk2 KFL/D, and NemoFL/Y) to CD19-Cre mice. All three
mutations similarly lead to a strong reduction of B cell
Figure 6. Increased B cell turnover in the spleens of CD19-Cre/
Ikk2 KFL/D mice compared with control mice. Analysis of BrdU incor-
poration by splenic B cells of mice of the indicated genotypes after 1 wk
of BrdU administration in the drinking water. Numbers indicate percent-
ages of BrdU-positive and BrdU-negative B cells.
Table I. Increased B Cell Turnover of CD19-Cre/Ikk2 KFL/D Splenic B Cells Compared to Control B Cells
Control B cells CD19-Cre/Ikk2 KFL/D B cells
BrdU  BrdU  BrdU  BrdU 
%  106 %  106 %  106 %  106
28 7.9 72 20 51 4.9 49 4.6
28 8.2 72 20 60 3.2 40 2.1
31 9.8 69 22.3 57 2.3 43 1.7
29 12 71 29.3 49 2.2 51 2.3
32 12.1 68 25.7
31 9.7 69 21.8
29.8   1.7 10   1.8 70.2   1.7 23.2   3.7 54.3   5.1 3.2   1.3 45.8   5.1 2.7   1.3
BrdU-incorporation by CD19-Cre/Ikk2 KFL/D and control splenic B cells was measured after 1 wk of BrdU administration. The proportions of
BrdU-positive (BrdU ) and negative (BrdU ) B cells of total splenic B cells are shown (%). The absolute B cell numbers for these fractions are shown
in millions ( 106). The last row indicates medium numbers and standard deviations.749 Pasparakis et al.
numbers in mutant mouse strains. CD19-Cre/Ikk2FL/D,
-Ikk2 KFL/D, or -NemoFL/Y mice have 3–4-fold reduced B
cells in the spleen and at least twofold reduced numbers in
recirculating BM B cells, lymph node B cells, and perito-
neal cavity B1 and B2 cells. Southern blot analysis of sorted
B cell populations revealed that whereas deletion efficiency
in IgM  BM B cells is as high as reported for CD19-Cre
mice and comparable to deletion observed in CD19-Cre/
Ikk2FL/WT mice, IgM  BM B cells are already counterse-
lected, most likely reflecting counterselection against recir-
culating B cells. In the transition from IM to FO B cells the
percentage of B cells with deleted alleles is reduced, indi-
cating that mature B cells lacking IKK activity are coun-
terselected. In the case of CD19-Cre/Ikk2FL/D and
-Ikk2 KFL/D mice  90% of the IM B cells have deleted
the floxed allele, whereas in follicular cells, which presum-
ably originate from the immature transitional cells, the pro-
portion of cells carrying the deletion ranges from 40 to
70%, clearly demonstrating counterselection of IkkD/D and
Ikk2 KD/D B cells. In CD19-Cre/NemoFL/Y mice, NemoD/Y
IM B cells are already counterselected, as evidenced by
Southern blot and cell counting. The fact that deletion of
NEMO, in contrast to the deletion of IKK2, seems to lead
to counterselection of cells already within the immature B
cell compartment may be explained in two ways. One ex-
planation is that in the absence of IKK2 some IKK-induced
NF- B activation can still occur while loss of NEMO
completely blocks IKK activity. Thus, in CD19-Cre/
Ikk2FL/D mice low levels of remaining NF- B activity
could be sufficient to sustain development of B cells to the
IM stage. In the CD19-Cre/NemoFL/Y mice the complete
absence of NF- B activity may lead to the loss of IM B
cells. Additionally or alternatively different turnover rates
of IKK2 and NEMO mRNA and protein could play a role.
The relatively long half-life of IKK2 (38) might ensure that
most B lineage cells of CD19-Cre/Ikk2FL/D mice develop
into FO B cells before they are devoid of this protein. The
half-life of NEMO could be shorter than that of IKK2,
leading to a rapid depletion of NEMO protein from IM B
cells that have deleted the nemoFL allele, resulting in the loss
Figure 7. Block of B cell influx from the BM in CD19-
Cre/Ikk2 KFL/D mice leads to disappearance of B cells of
the deleted genotype in the spleen. (A) Verification of the
block in B cell development after injection of anti–IL-7R
antibodies by FACS® analysis. Noninjected control mice
are compared with mice that had received injections of
anti–IL-7R antibodies for 4 wk. The genotypes are as indi-
cated above and cell surface markers are shown as coordi-
nates and gated cell populations are indicated in brackets.
The numbers next to boxed lymphocyte populations refer
to the percentages of live cells in the lymphocyte gate. (B)
Southern blot analysis of Cre mediated deletion in total
splenic B cells from two different (#1, #2) CD19-Cre/
Ikk2 KFL/D mice. The results are representative of six dif-
ferent mice. (C) Southern blot analysis of Cre mediated
deletion in total splenic B cells from three different (#1–3)
CD19-Cre/Ikk2 KFL/D mice that received anti–IL-7R an-
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of cells at this stage. The fact that CD19-Cre/Ikk2 KFL/D
mice display an intermediate phenotype with some loss of
deleted IM B cells, as demonstrated by the reduction of the
absolute cell numbers of IM B cells in these mice, is
compatible with both hypotheses, as the production of
IKK2 K may lead both to the earlier loss and to more
complete inhibition of IKK activity in comparison to the
CD19-Cre/Ikk2FL/D mice.
The picture seen in MZ B cells differs from that seen in
FO B cells. The remaining MZ B cells of the IKK-condi-
tional mutant mice crossed to CD19-Cre mice are nearly
completely devoid of the deleted genotype, clearly demon-
strating that Ikk2D/D, Ikk2 KD/D, and NemoD/Y MZ B cells
cannot be generated and/or persist. Recent evidence sug-
gests that MZ B cells represent a self-renewing separate
subset of B cells (39, 40). In this case cells of the deleted ge-
notype would disappear early during the generation of this
lineage and a subset of cells that have lost their ability to
delete would be sustained by self-renewal. Another view is
that MZ B cells are a highly antigen-selected population of
B cells (10, 41). During this selection process all B cells able
to undergo Cre-mediated deletion should have deleted the
loxP-flanked gene and subsequently disappeared. Thus, the
virtual absence of MZ B cells with a deleted genotype in
IKK conditional-CD-19Cre mice could be due to the fact
that the MZ B cell compartment is not constantly refilled
with B cells that recently acquired the deleted genotype as
is the follicular compartment. Alternatively, the absence of
MZ B cells with deleted nemo or ikk2 alleles could mean
that MZ B cells are more dependent on IKK-induced NF-
 B activity then other B cell populations. This explanation,
which does not exclude the former, is supported by the
specific loss of MZ B cells in p50-deficient mice (10).
Mature splenic B cells do not proliferate much (39, 42,
43), so that in a BrdU incorporation experiment over the
period of 1 wk most of the BrdU-positive B cells in the
spleen represent IM B cells from the BM (42). Roughly
twice as many CD19-Cre/Ikk2 KFL/D and CD19-Cre/
NemoFL/Y splenic B cells stain positive for BrdU after 1 wk
of BrdU administration compared with control B cells.
This means that recently generated B cells constitute a
larger fraction of total splenic B cells in mutant compared
with control mice despite the reduction in B cell numbers
in mutant mice. Thus, CD19-Cre/Ikk2 KFL/D mice con-
tain a higher percentage of short-lived splenic B cells than
do WT mice. These short-lived B cells should be cells that
carry two deleted alleles and are on their way to lose their
ability to signal through the IKK complex and subsequently
die. When B cell influx from the BM is blocked for 1 mo
by interfering with IL-7R signaling using injections of
anti–IL-7R antibodies, Ikk2 KD/D B cells completely dis-
appear from the spleens of these mice. The fact that only
Ikk2 KFL/D B cells remain in these CD19-Cre/Ikk2 KFL/D
mice shows that there must be a strong selection for cells in
which Cre is either absent or cannot function. FO B cells
were shown to have an average calculated half-life of 134 d
in the absence of replenishment of the splenic B cell pool
from the BM (39). As all of the Ikk2 KD/D FO B cells dis-
appear after 1 mo, this clearly demonstrates that IKK2 sig-
naling is essential for the maintenance of mature B cells.
We therefore conclude that mature B cells need IKK-
mediated survival signals.
Based on our experimental findings we envisage the fol-
lowing scenario: deletion of the conditional alleles in mice
containing the CD19-Cre transgene is initiated in the BM
and continues throughout the later stages of B cell develop-
ment. B cells that underwent Cre-mediated recombination
initially retain sufficient amounts of IKK2 or NEMO pro-
tein to allow development into IM B cells and some of
these cells progress further into the mature B cells compart-
ments. B cells that escape Cre-mediated deletion develop
normally into mature B cell subsets. Thus, the follicular B
cell compartment of these mice consists of a mixture of
cells that have already deleted and cells that retain loxP-
flanked alleles. The fact that blockade of B cell develop-
ment in the BM for 4 wk leads to the disappearance of all B
cells that have deleted the ikk2 K floxed alleles from the
spleen demonstrates that mature B cells cannot survive
without IKK2 activity.
It has been speculated that constitutive activation of NF-
 B by signaling through the B cell receptor (BCR) is es-
sential for B cell survival (13, 44). In agreement with this
idea B cells die by apoptosis upon inducible deletion of the
BCR (45). However, it was shown recently that while de-
letion of Bcl10 in mice selectively abolishes NF- B activa-
tion by the antigen receptor in B cells, Bcl10 /  mice
show normal B cell development. This argues against the
possibility that NF- B activation originating from the
BCR is needed for B cell survival (46). Therefore mature
peripheral B cells seem to depend on NF- B activating sig-
nals other than BCR cross-linking. These signals are likely
to be transmitted by interactions of TNF/TNF-R family
members such as BAFF/BAFF-R (47).
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